This Is MS Multiple Sclerosis Knowledge & Support Community

Name of drug/compound: NBI-5788 Manufacturer: Neurocrine Biosciences Location: San Diego, CA Current FDA Phase: II Treatment for: MS Progression Intended for RRMS Sub-types Mode of Action: Neurocrine scientists have taken the same amino acids that comprise a portion of myelin basic protein and alter...

Name of drug/compound: Intranasal Interferon Beta Manufacturer: Nastech Pharmaceutical Location: Bothell, WA Current FDA Phase: I Treatment for: MS Progression Intended for RRMS Sub-types Mode of Action: A nasal form of interferon beta may provide increased patient compliance and an improved efficac...

Name of drug/compound: Alferon N Injection (alpha interferons) Manufacturer: Hemispherx Biopharma, Inc. Location: Philadelphia Current FDA Phase: II Treatment for: MS Progression Intended for RRMS Sub-types Mode of Action: immune-modulation (aren't they still trying to conclusively figure out just w...

Name of drug/compound: Aimspro Manufacturer: Daval International Location: UK Current FDA Phase: II (?) - not FDA? Treatment for: MS Progression Intended for RRMS/PPMS/SPMS Sub-types Mode of Action: vaccine induced bioactive effector complex - polyclonal antibodies - anti-inflamatory properties Mode...

Name of drug/compound: Pixantrone Manufacturer: Cell Therapeutics Location: Seattle Current FDA Phase: n/a - planning phase I in near future Treatment for: MS Progression Intended for RRMS/SPMS Sub-types Mode of Action: analogue of mitoxantrone Mode of Application: intravenous Website for more infor...

Name of drug/compound: NeuroVax Manufacturer: Immune Response Corporation Location: Carlsbad, California Current FDA Phase: II Treatment for: disease progression Intended for RRMS Sub-types Mode of Action: NeuroVax is composed of a combination of TCR peptides from three families (BV5S2, BV6S5, and B...

I'm taking the lazy way out here, but this is a link to a really good summary put together in April 2004 by ING on the "MS Market" which includes a great listing of therapies in the clinical trial process.

http://sykepleier.net/filer/ms_market_report.pdf